16th Aug 2016 12:20
Abzena plc
Director / PDMR Shareholding and Exercise of options
Cambridge, UK, 16 August 2016 - Abzena plc (AIM: ABZA, 'Abzena', the 'Company' or the 'Group') announces that on 16 August 2016, 75,000 new ordinary shares of £0.002 each in the Company ('Ordinary Shares') were issued and allotted following the exercise of share options by a director. The new Ordinary Shares rank pari passu with the Company's existing issued Ordinary Shares and have been admitted to trading on AIM under the Company's block admission.
Director | New Ordinary Shares resulting from option exercises | Direct and indirect interest in Ordinary Shares | % of issued share capital1 |
Anker Lundemose, Non-Executive Director | 75,000 | 75,000 | 0.1% |
1 As enlarged by the issue of 75,000 new Ordinary Shares pursuant to the option exercise.
Total voting rights
Following the issue of 75,000 new Ordinary Shares pursuant to the option exercise set out above, the Company's issued share capital comprises 137,130,555 Ordinary Shares with voting rights. No Ordinary Shares are held in Treasury. The total number of voting rights in the Company is therefore 137,130,555. This figure of 137,130,555 Ordinary Shares may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA's Disclosure Guidance and Transparency Rules.
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
1 Details of the person discharging managerial responsibilities/person closely associate
1(a) | Name | Anker Lundemose |
1(b) | Position / Status | Non-executive Director |
2 Reason for the Notification
2(a) | Reason | Exercise of Stock Options |
2(b) | Initial notification / amendment | Initial |
3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
3(a) | Name | Abzena plc |
3(b) | Legal Entity Identifier ("LEI") | n/a |
4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
4(a) | Description of the financial instrument, type of instrument
| Abzena plc ordinary shares of £0.002 each | |
| Identification code
| GB00BN65QN46 | |
4(b) | Nature of transaction | Exercise of 75,000 stock options
| |
4(c) | Price(s) and volumes(s) | Price | Volume |
|
| £0.0002 (exercise price) | 75,000
|
4(d) | Aggregated information | Price | Volume |
|
| £0.0002 (exercise price) | 75,000
|
4(e) | Date of transaction | 16 August 2016
| |
4(f) | Place of the transaction | N/a
| |
Enquiries:
Abzena plc John Burt, Chief Executive Officer Julian Smith, Chief Financial Officer
| +44 12 2390 3498 |
Cenkos Securities (Nominated Adviser and Broker) Ivonne Cantu
| +44 20 7397 8900 |
N+1 Singer (Joint Broker) Aubrey Powell / Liz Yong
| +44 20 7496 3000 |
Instinctif Partners Melanie Toyne Sewell / Rozi Morris | +44 20 7457 2020 |
About Abzena
Abzena (AIM: ABZA) provides proprietary technologies and complementary services to enable the development and manufacture of biopharmaceutical products, a growing area that requires specialist knowledge and expertise. The Group has a global customer base which includes the majority of the top 20 biopharmaceutical companies as well as large and small biotech companies and academic groups.
The term "Abzena inside" is used by Abzena to describe products that have been created using its proprietary technologies and are being developed by its partners, and include Composite Human Antibodies™ and ThioBridge™ Antibody Drug Conjugates (ADCs). Abzena has the potential to earn future licence fees, milestone payments and/or royalties on "Abzena inside" products.
Abzena offers the following services and technologies across its principal sites in Cambridge (UK), San Diego, California (USA) and Bristol, Pennsylvania (USA).
· Immunogenicity assessment, protein engineering to create humanized antibodies and deimmunised therapeutic proteins, and cell line development for manufacture.
· Contract process development and manufacture of biopharmaceuticals, including monoclonal antibodies, recombinant proteins, vaccines, and gene therapy and cell therapy products, for preclinical and clinical studies.
· Proprietary site-specific conjugation technologies for antibody drug conjugate development and solutions for optimizing the therapeutic properties of biopharmaceuticals.
· Contract chemistry and bioconjugation business focused on ADCs and is establishing the capability to manufacture ADCs to GMP standards.
For more information, please see www.abzena.com
Related Shares:
Abzena